AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00675857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NC-503 (eprodisate disodium)
Description: capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
Study NCT00675857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage: 4 capsules BID for 26 weeks
Study NCT03930459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static cold storage (SCS)
Description: The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
Study NCT02930538 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Completing a survey on RedCap
Study NCT03930459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Description: During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
Study NCT03287856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
Study NCT02932891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS topical
Description: topical treatment
Study NCT02583256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted QIV (aQIV)
Description: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Study NCT02583256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted QIV
Description: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
Study NCT01530126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-TCP + 0.3 mg/ml rhPDGF-BB in buffer
Description: B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
Study NCT01530126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B-TCP + 1.0 mg/ml rhPDGF-BB in buffer
Description: B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
Study NCT01530126 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B-TCP +buffer
Description: B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
Study NCT00546715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Oral Solution, Oral, Single Dose
Study NCT00546715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, Single Dose
Study NCT04313920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: 50 g Carbohydrate
Study NCT01993108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: One dose 40mgs of methylphenidate one hour before fMRI scanning.
Study NCT01993108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: One dose 40mgs of naltrexone one hour before fMRI scanning.
Study NCT01993108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One dose of placebo one hour before fMRI scanning.
Study NCT03337633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menu design
Description: Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
Study NCT02346071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy.
Study NCT02346071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services.
Study NCT00519649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B Kinder
Description: Intramuscular injection, 1 dose
Study NCT01375218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pavlik Brace
Description: Pavlik Brace
Study NCT01375218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plastizote Brace
Description: Plastizote Brace
Study NCT01148628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD 001 in combination with Caelyx
Description: RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
Study NCT00586677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Child Interaction Therapy
Description: Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
Study NCT00586677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Safety
Description: Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
Study NCT00586677 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Relationships
Description: Sixteen one-hour sessions for children age 0-2 provided in-home.
Study NCT03583931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS Decortication
Description: Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
Study NCT03583931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinolytic Therapy
Description: Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
Study NCT01584804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Su-Huang antitussive capsule
Description: Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
Study NCT01584804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
Study NCT02753608 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Collection of exhaled breath condensate
Description: An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
Study NCT01285206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon polymer warming blanket
Description: Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
Study NCT00358007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTV Reduction
Description: The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
Study NCT02669459 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod
Description: 12,5 mg imiquimod three times per week during 16 weeks
Study NCT02669459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ
Description: surgical treatment for CIN, current gold standard
Study NCT02316080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental bleaching
Description: Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
Study NCT02316080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Desensitizing therapy
Description: Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
Study NCT00348985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Study NCT00348985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT00348985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT03491826 — intervention group
Intervention type: BIOLOGICAL
Intervention: rupture of membrane
Study NCT03214107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
Study NCT03214107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snack
Description: Full snack or Distributed snack
Study NCT01695135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Study NCT01695135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (4 tablets) taken orally once daily
Study NCT01695135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg tablet taken orally twice daily
Study NCT01488526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF treatment
Description: About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
Study NCT03930693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Study NCT01010282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin and Polysorbate 80 based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study NCT01010282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study NCT01010282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
Description: 1-2 drops in each eye, as needed, but at least twice daily
Study NCT03025724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan Kerastick
Description: Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
Study NCT03025724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light source
Description: At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
Study NCT03025724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participant satisfaction survey
Description: Participants will be asked to fill out a satisfaction survey.
Study NCT02385812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography Annual scan x3
Description: Annual scan x3
Study NCT02385812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography Baseline scan only
Description: Baseline scan only
Study NCT03117387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the level of neuromuscular blockade
Description: Study participant were not prospectively exposed to an intervention. Administration of a moderate or deep neuromuscular blockade is at the discretion of the attending anesthesiologist. Study participants only received diagnostic non-invasive monitoring. In routine clinical care the neuromuscular blockade is monitored non-invasively by either acceleromyography, electromyography or by the TOF-Cuff. In this study participants were monitored by the monitors and were not exposed to any additional risk and no effect of an intervention was assessed in this study.
Study NCT03424538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation
Description: 5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
Study NCT02753608 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of exhaled breath condensate
Description: An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
Study NCT02006901 — intervention group
Intervention type: PROCEDURE
Intervention: microdecompression
Description: a minimal invasive surgical technique
Study NCT02168907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02168907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT02168907 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT02168907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00555620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Study NCT02562716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02562716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03276806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: tobacco dependence/smoking cessation counseling
Description: Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
Study NCT02562716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02562716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02562716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02562716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatectomy
Description: Undergo pancreatectomy
Study NCT01522716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
Study NCT03276806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco dependence/smoking cessation counseling
Description: Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
Study NCT03276806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDM
Description: SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
Study NCT03276806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
Study NCT03276806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDCT brochure
Description: A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
Study NCT00331799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
Study NCT04579640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol
Study NCT01775371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia (PCA)
Description: Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
Study NCT01775371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual opioid analgesia determined by the provider
Study NCT00651339 — intervention group
Intervention type: DRUG
Intervention: botox
Description: botox injection
Study NCT05054998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT05054998 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT02006901 — intervention group
Intervention type: PROCEDURE
Intervention: laminectomy
Description: The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
Study NCT04257773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Forgiveness Workbook Intervention
Description: Participants will be asked to complete the REACH Forgiveness Workbook
Study NCT03128931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediatric SedLine forehead EEG sensor
Description: Pediatric EEG sensor.
Study NCT03252015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probe Drug Cocktail
Description: Administered orally
Study NCT03252015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probe Drug Cocktail
Description: Administered orally
Study NCT03252015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT03252015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03252015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02192307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Potassium oxalate
Study NCT02192307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Study NCT01991600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulphate
Study NCT01991600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferric iron oxide-organic acid (Fe-OA)
Study NCT00518531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: alendronate
Description: Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
Study NCT00518531 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: denosumab
Description: Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
Study NCT03073642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Education
Description: Together with hydrotherapy, patients will receive pain therapeutic education